Observational studyFrontiers in immunology2020
Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Open access · goldAbstract readObservational Study
In one paragraph
Observational study in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Innovative technologies and their clinical prospects for early lung cancer screening.Clinical and experimental medicine · 2025Pooled it
- Monocyte-related markers as predictors of immune checkpoint inhibitor efficacy and immune-related adverse events: a systematic review and meta-analysis.Cancer metastasis reviews · 2025Pooled it
- A pathomics model for predicting lactate-related prognostic risk groups and their biological mechanisms in lung adenocarcinoma.Translational cancer research · 2026Article
- A nomogram prediction model for brain metastases in patients with lung adenocarcinoma.Oncology letters · 2026Article
- Soluble Isoforms of PD-1 and PD-L1 in Non-Small Cell Lung Cancer: Correlation with Tumor Stage, Longitudinal Analysis and Prognostic Implications.Journal of personalized medicine · 2026Article
- Dynamic serum tumor-marker and immune-inflammatory biomarker changes for risk stratification of immune checkpoint inhibitor-associated myasthenia gravis in non-small cell lung cancer.Frontiers in immunology · 2026Article
- Clinical efficacy and safety of sintilimab injection plus chemotherapy in patients with stage IB-IIIB non-small cell lung cancer.Pakistan journal of medical sciences · 2025Article
- Efficacy and safety of immunotherapy in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: a multicenter retrospective study.Therapeutic advances in medical oncology · 2025Article
- Serum tumor markers and outcomes in lung cancer patients with brain metastases: a retrospective longitudinal cohort study.Translational lung cancer research · 2024Article
- Immunological profiling for short-term predictive analysis in PD-1/PD-L1 therapy for lung cancer.BMC cancer · 2024Article
- Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management.Oncotarget · 2024Article
- MUC16: clinical targets with great potential.Clinical and experimental medicine · 2024Review
- The establishment of PD-1 inhibitor treatment prognosis model based on dynamic changes of peripheral blood indexes in patients with advanced lung squamous cell carcinoma.Frontiers in oncology · 2024Article
- Analysis of the treatment efficacy and prognostic factors of PD-1/PD-L1 inhibitors for advanced gastric or gastroesophageal junction cancer: a multicenter, retrospective clinical study.Frontiers in immunology · 2024Article
- Article
- Metabolic phenotypes, serum tumor markers, and histopathological subtypes in predicting bone metastasis: analysis of 695 patients with lung cancer in China.Quantitative imaging in medicine and surgery · 2023Article
- Article
- Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression.Frontiers in immunology · 2023Article
- Efficacy of immune checkpoint inhibitors along with chemotherapy in non-small cell lung cancer and the impact on adverse reactions and serum tumor markers.American journal of translational research · 2023Article
- Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study.Therapeutic advances in medical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Zhibo ZhangDepartment of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Fang YuanDepartment of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Runzhe ChenDepartments of Thoracic/Head and Neck Medical Oncology and Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Ye LiDepartment of Radiotherapy, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Junxun MaDepartment of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Xiang YanDepartment of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Lijie WangDepartment of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Fan ZhangDepartment of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Haitao TaoDepartment of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Dong GuoBeiGene (Shanghai) Co., Ltd., Shanghai, China.
Zhiyue HuangBeiGene (Shanghai) Co., Ltd., Shanghai, China.
Sujie ZhangDepartment of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Xiaoyan LiDepartment of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Xiaoyu ZhiDepartment of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Xiangwei GeDepartment of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Yi HuDepartment of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Jinliang WangDepartment of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Chinese PLA General Hospital · CNPLA Academy of Military Science · CNBeiGene (China) · CNThe University of Texas MD Anderson Cancer Center · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Treatment OutcomeAdultAgedAged, 80 and overAntigens, NeoplasmAsian PeopleBiomarkers, TumorCA-125 AntigenCarcinoembryonic AntigenCarcinoma, Non-Small-Cell LungFemaleHumansImmune Checkpoint InhibitorsKeratin-19Lung NeoplasmsMaleantigen CYFRA21.1Antigens, NeoplasmBiomarkers, TumorCA-125 AntigenCarcinoembryonic AntigenImmune Checkpoint InhibitorsKeratin-19Membrane ProteinsMUC16 protein, humanChinese patientsimmune checkpoint inhibitorsnon-small cell lung cancerprognostic biomarkerserum tumor markers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.